The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
DE10064797A1
Combination pack useful for the treatment of e.g. deep vein thrombosis and post-operative thrombosis, containing oral and parenteral formulations of thrombin inhibitor prodrugs
DE10064823A1
New (hetero)aryl-substituted aliphatic carboxylic acid derivatives, useful as integrin receptor ligands for treating, e.g. atherosclerosis, restenosis, rheumatoid arthritis, cancer, osteoporosis or hypertension
DE10049937A1
New sugar-modified amidine and guanidine compounds, useful as competitive inhibitors of serine protease, e.g. for treating thrombosis
GB0023610D0
Therapeutic agents
DE10046541A1
Oral dosage form useful as nutritional supplement or medicament comprises solid dispersion of ubiquinone in thermoplastic matrix
GB0021147D0
Chemical process
GB0021145D0
Chemical process
DE10038571A1
Compositions and dosage forms for use in the oral cavity in the treatment of mycoses
DE10031390A1
Pyrimidine derivatives and their use for the prophylaxis and therapy of cerebral ischemia
DE10031391A1
Bicyclic compounds and their use for the prophylaxis and therapy of cerebral ischemia
DE10031389A1
Pyrimidine derivatives and their use for the prophylaxis and therapy of cerebral ischemia
AU6429000A
Screening method
GB0007376D0
Therapeutic agents
DE10013289A1
Storage-stable formulations containing diuretic torasemide, are solids or semi-solids containing the active agent in non-crystalline form, e.g. as solid solution in vinyl pyrrolidone polymer matrix
